Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BI 765049 |
Trade Name | |
Synonyms | BI-765049|BI765049 |
Drug Descriptions |
BI 765049 is a bispecific T-cell engager (BiTE) that targets tumor-expressed NCR3LG1 (B7-H6) and CD3 expressed on T-cells, potentially leading to increased migration of T-lymphocytes to the tumor, resulting in tumor cell apoptosis and decreased tumor growth (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS3175-TPS3175). |
DrugClasses | CD3 Antibody 99 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BI 765049 | BI 765049 | 0 | 1 |
BI 765049 + Ezabenlimab | BI 765049 Ezabenlimab | 0 | 1 |